Cannabis Use During Early Pregnancy Following Recreational Cannabis Legalization.


Journal

JAMA health forum
ISSN: 2689-0186
Titre abrégé: JAMA Health Forum
Pays: United States
ID NLM: 101769500

Informations de publication

Date de publication:
01 Nov 2024
Historique:
medline: 1 11 2024
pubmed: 1 11 2024
entrez: 1 11 2024
Statut: epublish

Résumé

It is unknown whether state recreational cannabis legalization (RCL) is related to increased rates of prenatal cannabis use or whether RCL-related changes vary with cannabis screening methods or the local policy environment. To test whether RCL in California was associated with changes in prenatal cannabis use rates, whether changes were evident in both self-report and urine toxicology testing, and whether rates varied by local policies banning vs allowing adult-use retailers post-RCL. This population-based time-series study used data from pregnancies in Kaiser Permanente Northern California universally screened for cannabis use during early pregnancy by self-report and toxicology testing from January 1, 2012, to December 31, 2019. Analyses were conducted from September 2022 to August 2024. California state RCL passage (November 9, 2016) and implementation of legal sales (January 1, 2018) were examined with a 1-month lag. Local policies allowing vs banning medical retailers pre-RCL and adult-use retailers post-RCL were also examined. Any prenatal cannabis use was based on screening at entrance to prenatal care (typically at 8-10 weeks' gestation) and defined as (1) a positive urine toxicology test result or self-report, (2) a positive urine toxicology test result, or (3) self-report. Interrupted time series models were fit using Poisson regression, adjusting for age, race and ethnicity, and neighborhood deprivation index. The sample of 300 993 pregnancies (236 327 unique individuals) comprised 25.9% Asian individuals, 6.4% Black individuals, 26.0% Hispanic individuals, 37.7% White individuals, and 4.1% individuals of other, multiple, or unknown race, with a mean (SD) age of 30.3 (5.4) years. Before RCL implementation, rates of prenatal cannabis use rose steadily from 4.5% in January 2012 to 7.1% in January 2018. There was no change in use rates at the time of RCL passage (level change rate ratio [RR], 1.03; 95% CI, 0.96-1.11) and a statistically significant increase in rates in the first month after RCL implementation, increasing to 8.6% in February 2018 (level change RR, 1.10; 95% CI, 1.04-1.16). Results were similar when defining prenatal cannabis use by (1) a toxicology test or (2) self-report. In local policy analyses, the post-RCL implementation increase in use was only found among those in jurisdictions allowing adult-use cannabis retailers (allowed RR, 1.21; 95% CI, 1.10-1.33; banned RR, 1.01; 95% CI, 0.93-1.10). In this time-series study, RCL implementation in California was associated with an increase in rates of cannabis use during early pregnancy, defined by both self-report and toxicology testing, driven by individuals living in jurisdictions that allowed adult-use retailers.

Identifiants

pubmed: 39485336
pii: 2825387
doi: 10.1001/jamahealthforum.2024.3656
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e243656

Auteurs

Kelly C Young-Wolff (KC)

Division of Research, Kaiser Permanente Northern California, Pleasanton.
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco.

Natalie E Slama (NE)

Division of Research, Kaiser Permanente Northern California, Pleasanton.

Lyndsay A Avalos (LA)

Division of Research, Kaiser Permanente Northern California, Pleasanton.

Alisa A Padon (AA)

Public Health Institute, Oakland, California.

Lynn D Silver (LD)

Public Health Institute, Oakland, California.

Sara R Adams (SR)

Division of Research, Kaiser Permanente Northern California, Pleasanton.

Monique B Does (MB)

Division of Research, Kaiser Permanente Northern California, Pleasanton.

Deborah Ansley (D)

Regional Offices, Kaiser Permanente Northern California, Pleasanton.

Carley Castellanos (C)

Regional Offices, Kaiser Permanente Northern California, Pleasanton.

Cynthia I Campbell (CI)

Division of Research, Kaiser Permanente Northern California, Pleasanton.
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco.

Stacey E Alexeeff (SE)

Division of Research, Kaiser Permanente Northern California, Pleasanton.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH